The NCCN Guidelines provide evidence-based, consensus-driven guidance for cancer management to ensure that all patients receive preventive, diagnostic, therapeutic, and supportive services that are most likely to lead to optimal outcomes. They are intended to assist all individuals who impact decision-...
The NCCN guidelines describe a detailed assessment regarding to both etiology and pathophysiology, as well as specific cancer-related syndromes.9 These guidelines are also important in that they draw attention to NP as a medi- cal emergency. Still, there is no consensus on ...
By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your perso...
However, the magnitude of difference for both QLQ-OV28 and QLQ-C30, although statistically significant were within the ranges that are interpreted as ‘small’ [15] but nevertheless still clinically important according to published interpretation guidelines for MIDs [15]. Functional and selected ...
However, patients with a PI-RADS score 3 are equivocal in detecting clinically significant prostate cancer (csPCa). As a result, it may lead to low specificity and, therefore, overdiagnosis [6, 28, 30]. Additionally, according to the NCCN, some patients are recommended to undergo radical ...
[2] NCCN Guidelines For Patients: Lung Cancer Screening. [3] Ando S, Kimura H, Iwai N, et al. The significance of tumour markers as an indication for mediastinoscopy in non-small cell lung cancer[J]. Respirology, 2003, 8 (2):163-1 [4] 支修益 , 石远凯 , 于金明 . 中国原发性肺...
The recently announced 2017 NCCN guidelines are the first to incorporate ROS1 gene fusion detection into the first-line treatment plan for advanced NSCLC. As the main method of personalized medicine, targeted therapy mainly kills malignant tumor cells through gene or molecular selection, but hardly ...
case of non-enhancing disease. The results of these trials might expand the FDA approval indications of vorasidenib. To this point, the National Comprehensive Cancer Network (NCCN) guidelines list ivosidenib – an IDH1 inhibitor- as a treatment option for recurrent IDH1 mutant grade II gliomas an...
By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your perso...
Based on this Phase 3 DESTINY-Breast03 study, Enhertu has been added to the NCCN Clinical Practical Guidelines in Oncology as the Category 1 preferred regimen as second-line therapy for recurrent unresectable (local or regional) or Stage IV HER2-positive disease. ...